Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein
- 6 January 2012
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (2), 210-218
- https://doi.org/10.1111/j.1365-2125.2011.04083.x
Abstract
To determine pharmacokinetics (PK), pharmacodynamics (PD), tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP). The first in man (FIM) study investigated the safety, tolerability, pharmacodynamics and pharmacokinetics in healthy male subjects following administration of single oral doses. The study was performed using a randomized, single-blind, placebo-controlled, single dose-escalation design. Thirty-eight young healthy male subjects (aged 20-45 years) received an oral dose of 5, 12.5, 25 or 50 mg BAY 60-5521 (n= 28) or were treated with a placebo (n= 10). In all four dose steps, only one adverse event (25 mg; mild skin rash) was considered drug related. Clinical laboratory parameters showed no clinically relevant changes. A clear dose-dependent CETP inhibition could be demonstrated starting at a dose of 5 mg. At a dose of 25 mg, a CETP inhibition >50% over 18 h was observed. After 50 mg, CETP inhibition >50% lasted more than 50 h. Twenty-four h after administration mean HDL-C-values showed a nearly dose-proportional increase. Following administration of 50 mg, a significant HDL-C increase of about 30% relative to baseline values was found. BAY 60-5521 was slowly absorbed reaching maximum concentrations in plasma after 4 to 6 h. The disposition in plasma was multi-exponential with an estimated mean terminal half-life of 76 to 144 h. BAY 60-5521 was clinically safe and well tolerated. No effects on heart rate, blood pressure and ECG recordings were observed during the study. A clear pharmacodynamic effect on CETP inhibition and HDL could be demonstrated.Keywords
This publication has 27 references indexed in Scilit:
- Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modellingBritish Journal of Clinical Pharmacology, 2011
- Novel tetrahydrochinoline derived CETP inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- JTT-705: is there still future for a CETP inhibitor after torcetrapib?Expert Opinion on Investigational Drugs, 2008
- Heart Disease and Stroke Statistics—2008 UpdateCirculation, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- Atherothrombosis and High-Risk PlaqueJournal of the American College of Cardiology, 2005
- Dibenzodioxocinones—A new class of CETP inhibitorsBioorganic & Medicinal Chemistry Letters, 2005
- Is There a Need for Cholesteryl Ester Transfer Protein Inhibition?Arteriosclerosis, Thrombosis, and Vascular Biology, 2003